Laura M. Huppertz - Concepedia

Author

Laura M. Huppertz

University Medical Center Freiburg ORCID

Also Known As

L. Huppertz, L. M. Huppertz, L.-M. Huppertz, L.M. Huppertz, Laura Huppertz, Laura M Huppertz, Laura M. Huppertz

Publications

678

Citations

H-Index

Concepts

All Affiliations

University Medical Center Freiburg University of Freiburg University of Bern

About

Laura M. Huppertz is an author at University Medical Center Freiburg specializing in medicine, pharmacology, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	261
2	Biochemistry	4	4	101
3	Natural Sciences	3	3	67
4	Social Sciences	1	1	28
5	Emergency Medicine	1	1	16

Laura M. Huppertz

Publications

617

Citations

H-Index

Page 1

	Year	Citations
Detection and identification of the designer benzodiazepine flubromazepam and preliminary data on its metabolism and pharmacokinetics Bjoern Moosmann, Laura M. Huppertz, Melanie Hutter, Journal of Mass Spectrometry	2013	90
Characterization of the four designer benzodiazepines clonazolam, deschloroetizolam, flubromazolam, and meclonazepam, and identification of their in vitro metabolites Laura M. Huppertz, Philippe Bisel, Folker Westphal, Forensic Toxicology Pharmacological StudyDrug DesignMedicineVitro MetabolitesOrganic Chemistry	2015	66
Flubromazolam – Basic pharmacokinetic evaluation of a highly potent designer benzodiazepine Laura M. Huppertz, Bjoern Moosmann, Volker Auwärter Drug Testing and Analysis	2017	60
A comprehensive library‐based, automated screening procedure for 46 synthetic cannabinoids in serum employing liquid chromatography‐quadrupole ion trap mass spectrometry with high‐temperature electrospray ionization Laura M. Huppertz, Stefan Kneisel, Volker Auwärter, Journal of Mass Spectrometry	2014	54
Characterization of the designer benzodiazepine pyrazolam and its detectability in human serum and urine Bjoern Moosmann, Melanie Hutter, Laura M. Huppertz, Forensic Toxicology Designer Benzodiazepine PyrazolamMedicineForensic ToxicologyDrug TestPharmacotherapy	2013	50
Structural characterization and pharmacological evaluation of the new synthetic cannabinoid CUMYL‐PEGACLONE Verena Angerer, Lukas Mogler, Jan‐Patrick Steitz, Drug Testing and Analysis	2017	45
Characterization and <i>in vitro</i> phase I microsomal metabolism of designer benzodiazepines — an update comprising adinazolam, cloniprazepam, fonazepam, 3‐hydroxyphenazepam, metizolam and nitrazolam Bjoern Moosmann, Philippe Bisel, Florian Franz, Journal of Mass Spectrometry Psychotropic MedicationPsychopharmacologyPharmacotherapyDesigner BenzodiazepinesExperimental Pharmacology	2016	40
Phase I metabolism of the recently emerged synthetic cannabinoid CUMYL‐PEGACLONE and detection in human urine samples Lukas Mogler, Maurice Wilde, Laura M. Huppertz, Drug Testing and Analysis	2018	36
Structure-metabolism relationships of valine and tert-leucine-derived synthetic cannabinoid receptor agonists: a systematic comparison of the in vitro phase I metabolism using pooled human liver microsomes and high-resolution mass spectrometry Florian Franz, Hanna Jechle, Maurice Wilde, Forensic Toxicology Cannabis UseBiochemistryFunctional SelectivityMedicineStructure-metabolism Relationships	2019	34
‘Psychotropics caught in a trap’ – Adopting a screening approach to specific needs Jürgen Kempf, Jessica Traber, Volker Auwärter, Forensic Science International Specific NeedsPsychiatric EvaluationPsychiatryPsychotic Disorder‘ Psychotropics	2014	28

Page 1